Investor Presentaiton
Product Pipeline
HLX51
OX40
IND
Solid tumors, lymphoma
Phase I
HLX10 (1) (serplulimab)+HLX60(2)
PD-1+GARP
Solid tumors
Phase II
HLX10 (serplulimab)+HANBEITAI
PD-1+VEGF
mCRC 1L
HLX6018
GARP/TGF-ẞ1
IPF
HLX17 (pembrolizumab)
PD-1
MEL, NSCLC, EC, HNSCC, CRC, HCC,
TNBC
HLX99
Polypharmacology
ALS
HLX60(2)
GARP
Solid tumors, lymphoma
HLX53
TIGIT
Solid tumors, lymphoma
HLX42(4)
EGFR ADC
Solid tumors
HLX101) (serplulimab)+HLX07
PD-1+EGFR
HNSCC, NPC, GC, ESCC,
sqNSCLC
HLX10 (serplulimab)+HLX26+chemo
PD-1+LAG-3
NSCLC 1L
Phase III
HLX10) (serplulimab)+chemo
PD-1
ES-SCLC 1L
HLX10) (serplulimab) +chemo
PD-1
Neo/adjuvant treatment for GC
HLX10) (serplulimab) +chemo
+radio
PD-1
LS-SCLC 1L
HLX04-0 (8)
HLX07(6)
EGFR
Solid tumors (cSCC)
VEGF
WetAMD
NDA
HLX10 (serplulimab)+chemo
PD-1
ES-SCLC 1L
HLX10) (serplulimab)+HANBEITAI
PD-1+VEGF
nsNSCLC 1L
HLX02 (trastuzumab)(12)
HER2
Breast cancer, MGC
MAA
Marketed
HANSIZHUANG (serplulimab)(1)
PD-1
MSI-H solid tumors, sqNSCLC, ES-
SCLC, ESCC
HANLIKANG (rituximab)(14)
CD20
NHL, CLL, RA
(15)
(12)
HANQUYOU (trastuzumab)"
HER2
Breast cancer, MGC
HANDAYUAN (adalimumab)(13)
TNF-a
PJIA, pediatric plaque psoriasis, etc.
HANDAYUAN (adalimumab)(13)
TNF-a
RA, AS, psoriasis, uveitis
HLX43(3)
PD-L1 ADC
Solid tumors
HLX22+HANQUYOU
HER2+HER2
GC
HLX11 (pertuzumab)(9)
HER2
Neoadjuvant treatment of breast cancer
HLX05 (cetuximab) (5)
EGFR
mCRC, HNSCC
HLX208(7)
BRAF V600E
LCH/ECD, solid tumors (i.e. MEL, TC,
mCRC, NSCLC)
HLX14 (denosumab)(10)
RANKL
Osteoporosis
HLX15 (daratumumab)
CD38
Multiple myeloma
HLX208(7) +HLX10 (1)
(serplulimab)
BRAF V600E+PD-1
NSCLC
HLX78 (Lasofoxifene) (11)
SERM
Breast cancer
HANBEITAI (bevacizumab)
VEGF
(16)
mCRC, advanced, metastatic or recurrent
NSCLC, GBM, etc.
HLX13 (ipilimumab)
CTLA-4
MEL, RCC, CRC, HCC, NSCLC, MPM, EC
Innovative mAb
Innovative fusion protein
mAb biosimilar
Innovative ADC
Bridging study in
Innovative small molecule
BLA under FDA review
MAA
MAA application
in the EU
the US
MRCT
The first Chinese mAb approved both in
the Chinese mainland and the EU
(1) Approved in China and Indonesia, business partners: KGbio/Fosun Pharma/Intas. (2) IND approvals obtained in Australia. (3) IND approvals obtained in China/the US. (4) IND approvals obtained in China/the US, and received fast track designation by FDA. (5) Business partner:
Shanghai Jingze. (6) IND approvals obtained in China/the US. (7) Exclusive right in China. (8) IND approvals obtained in China/Australia/the US/Singapore/the EU countries, etc. Business partner: Essex. (9) IND approvals obtained in China/the EU. Business partner: Organon. (10) IND
approvals obtained in China/the EU/Australia. Business partner: Organon. (11) Exclusive rights in China, MRCT phase III global enrolment is in process. (12) Approved in 40+ countries, including China, the UK, Germany, France and Australia, trade name registered in Europe:
ZercepacⓇ, trade name registered in Australia: TuzucipⓇ and TrastucipⓇ. Business partners: Accord/ Cipla/ Jacobson/ Elea/ Eurofarma/ Abbott/KGbio. (13) Business partners: Wanbang/Getz Pharma. (14) The first biosimilar approved in China. Business partners: Fosun Pharma/FARMA
DE COLOMBIA/Eurofarma/Abbott. (15) The first rituximab approved for the indication in China. (16) Business partner: Eurofarma.
22
© 2024 Henlius.
2 HenliusView entire presentation